Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York. This presentation is significant for investors and the oncology community as it provides updates on the company's progress in developing innovative cancer therapeutics that address critical unmet medical needs.
The company's lead candidate, ENV105, represents a novel approach to overcoming drug resistance in cancer treatment. ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer therapies. The elevation of CD105 in response to standard cancer treatments often results in resistance and disease relapse, making it a significant challenge in oncology. By targeting CD105, ENV105 aims to reverse this drug resistance and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV105 is advancing through clinical trials with a Phase 2 study for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. These trials address significant unmet medical needs in oncology, particularly for patients who have developed resistance to existing treatments. The development of ENV105 could potentially transform cancer treatment paradigms by providing a solution to one of the most persistent problems in oncology - therapeutic resistance.
For investors and stakeholders seeking additional information, the latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. The full press release detailing the conference presentation can be accessed at https://ibn.fm/mdybH. This conference presentation provides an important opportunity for the investment community to gain insights into Kairos Pharma's clinical progress and strategic direction, which could have significant implications for cancer treatment development and patient outcomes worldwide.
